Intradermal skin test with mRNA vaccines as a surrogate marker of T cell immunity in immunocompromised patients.

Details

Ressource 1Download: 37321353_BIB_9DA429039D3E.pdf (8532.45 [Ko])
State: Public
Version: Final published version
License: Not specified
Serval ID
serval:BIB_9DA429039D3E
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Intradermal skin test with mRNA vaccines as a surrogate marker of T cell immunity in immunocompromised patients.
Journal
The Journal of infection
Author(s)
Fallet B., Foglierini M., Porret R., Alcaraz-Serna A., Sauvage C., Jenelten R., Caplanusi T., Gilliet M., Perez L., Fenwick C., Genolet R., Harari A., Bobisse S., Gottardo R., Pantaleo G., Muller Y.D.
ISSN
1532-2742 (Electronic)
ISSN-L
0163-4453
Publication state
Published
Issued date
08/2023
Peer-reviewed
Oui
Volume
87
Number
2
Pages
111-119
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
Intradermal skin test (IDT) with mRNA vaccines may represent a simple, reliable, and affordable tool to measure T cell response in immunocompromised patients who failed to mount serological responses following vaccination with mRNA covid-19 vaccines.
We compared anti-SARS-CoV-2 antibodies and cellular responses in vaccinated immunocompromised patients (n = 58), healthy seronegative naive controls (NC, n = 8), and healthy seropositive vaccinated controls (VC, n = 32) by Luminex, spike-induced IFN-γ Elispot and an IDT. A skin biopsy 24 h after IDT and single-cell RNAseq was performed in three vaccinated volunteers.
Twenty-five percent of seronegative NC had a positive Elispot (2/8) and IDT (1/4), compared to 95% (20/21) and 93% (28/30) in seropositive VC, respectively. Single-cell RNAseq data in the skin of VC showed a predominant mixed population of effector helper and cytotoxic T cells. The TCR repertoire revealed 18/1064 clonotypes with known specificities against SARS-CoV-2, among which six were spike-specific. Seronegative immunocompromised patients with positive Elispot and IDT were in 83% (5/6) treated with B cell-depleting reagents, while those with negative IDT were all transplant recipients.
Our results indicate that delayed local reaction to IDT reflects vaccine-induced T-cell immunity opening new perspectives to monitor seronegative patients and elderly populations with waning immunity.
Keywords
Aged, Humans, T-Lymphocytes, COVID-19 Vaccines, COVID-19/diagnosis, COVID-19/prevention & control, SARS-CoV-2, Biomarkers, mRNA Vaccines, Antibodies, Viral, Immunocompromised Host, Skin Tests, Vaccination, COVID, Immunosuppression, Skin, T cells, Vaccine
Pubmed
Web of science
Open Access
Yes
Create date
16/06/2023 12:54
Last modification date
25/01/2024 7:41
Usage data